newsfilter
← Latest News
GlobeNewswire·

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies have demonstrated potential advantages o